Toxicity of macrolide antibiotics on isolated heart mitochondria: A justification for their cardiotoxic adverse effect

Xenobiotica

Volumn 46, Issue 1, 2016, Pages 82-93

  Salimi, Ahmad ^a   Eybagi, Sadaf ^a   Seydi, Enayatollah ^a   Naserzadeh, Parvaneh ^a   Kazerouni, Negar Panahi ^b   Pourahmad, Jalal ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Azithromycin; cardiotoxicity; clarithromycin; erythromycin; heart mitochondria

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME C; DELAYED RECTIFIER POTASSIUM CHANNEL; ERYTHROMYCIN; MACROLIDE; POTASSIUM CHANNEL HERG; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; ANTIINFECTIVE AGENT; CARDIOTOXIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASSAY; CARDIOTOXICITY; CONTROLLED STUDY; CYTOCHROME C RELEASE ASSAY; ELECTROPHYSIOLOGICAL PROCEDURES; HEART ARRHYTHMIA; HEART MITOCHONDRION; HEART MUSCLE CELL; ISOLATED HEART; MALE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRION SWELLING; NONHUMAN; POTASSIUM CONDUCTANCE; QT PROLONGATION; RAT; TORSADE DES POINTES; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; ENZYMOLOGY; IN VITRO STUDY; LIVER MITOCHONDRION; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; SECRETION (PROCESS); WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CARDIOTOXINS; CLARITHROMYCIN; CYTOCHROMES C; ERYTHROMYCIN; IN VITRO TECHNIQUES; MACROLIDES; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, HEART; MITOCHONDRIA, LIVER; MITOCHONDRIAL SWELLING; MYOCYTES, CARDIAC; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUCCINATE DEHYDROGENASE;

EID: 84954490373     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1046975     Document Type: Article

References (49)

1. Amsden GW. (1996). Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 18:56-72.
2. Antzelevitch C, Sun Z-Q, Zhang Z-Q, Yan G-X. (1996). Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 28:1836-48.
3. Araújo L, Demoly P. (2008). Macrolides allergy. Curr Pharm Des 14: 2840-62.
4. Baracca A, Sgarbi G, Solaini G, Lenaz G. (2003). Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F 0 during ATP synthesis. Biochim Biophys Acta Bioenerg 1606:137-46.
5. Ben-Shoshan M, Moore A, Primeau M. (2009). Anaphylactic reaction to clarithromycin in a child. Allergy 64:962-3.
6. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem 72:248-54.
7. Brown DA, O'Rourke B. (2010). Cardiac mitochondria and arrhythmias. Cardiovasc Res 88:241-9.
8. Camilleri M, Parkman HP, Shafi MA, et al. (2013). Clinical guideline: management of gastroparesis. Am J Gastroenterol 108:18-37; quiz 38.
9. Chey WD, Wong BC. (2007). American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808-25.
10. Christopher K, Hyatt PA, Horkan C, Yodice PC. (2002). Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 97: 489-90.
11. Cortassa S, Aon MA, Marbán E, et al. (2003). An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 84:2734-55.
12. Curran ME, Splawski I, Timothy KW, et al. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803.
13. Daleau P, Lessard E, Groleau MF, Turgeon J. (1995). Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91:3010-16.
14. De Vries H, Arendzen A, Kroon A. (1973). The interference of the macrolide antibiotics with mitochondrial protein synthesis. Biochim Biophys Acta Nucl Acids Protein Synth 331:264-75.
15. Duewelhenke N, Krut O, Eysel P. (2007). Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents chemother 51:54-63.
16. Dykens JA, Will Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12:777-85.
17. Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J. (2015). A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica 45:79-87.
18. Fazekas T, Krassoi I, Lengyel C, et al. (1998). Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin Electrophysiol 21:147-50.
19. Gaynor M, Mankin AS. (2003). Macrolide antibiotics: binding site, mechanism of action, resistance. Curr Top Med Chem 3:949-61.
20. Guzy RD, Schumacker PT. (2006). Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 91:807-19.
21. Hensey C, Keane D. (2008). Clarithromycin induced torsade de pointes. Irish J Med Sci 177:67-8.
22. Ibrahim NG, Burke JP, Beattie DS. (1974). The sensitivity of rat liver and yeast mitochondrial ribosomes to inhibitors of protein synthesis. J Biol Chem 249:6806-11.
23. Jafarian I, Eskandari MR, Mashayekhi V, et al. (2013). Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol Mech Methods 23:617-23.
24. Kalghatgi S, Spina CS, Costello JC, et al. (2013). Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci Transl Med 5:192ra185.
25. Kanno T, Sato EF, Muranaka S, et al. (2004). Oxidative stress underlies the mechanism for Ca2+-induced permeability transition of mitochondria. Free Rad Res 38:27-35.
26. Kowaltowski AJ, Castilho RF, Vercesi AE. (2001). Mitochondrial permeability transition and oxidative stress. FEBS Lett 495:12-15.
27. Lockwood AM, Cole S, Rabinovich M. (2010). Azithromycin-induced liver injury. Am J Health Syst Pharm 67:810-14.
28. Lu HR, Vlaminckx E, Van de Water A, et al. (2006). In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 553:229-39.
29. Maheshwai N. (2007). Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? Arch Disease Childhood 92:271-3.
30. Newmeyer DD, Ferguson-Miller S. (2003). Mitochondria: releasing power for life and unleashing the machineries of death. Cell 112: 481-90.
31. Niederman MS, Mandell LA, Anzueto A, et al. (2001). Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730-54.
32. O'Rourke B, Ramza BM, Marban E. (1994). Oscillations of membrane current and excitability driven by metabolic oscillations in heart cells. Science 265:962-6.
33. Pereira CV, Moreira AC, Pereira SP, et al. (2009). Investigating druginduced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 4:34-54.
34. Pourahmad J, Hosseini MJ, Eskandari MR, et al. (2010). Mitochondrial/ lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 40:763-71.
35. Pourahmad J, Mortada Y, Eskandari MR, Shahraki J. (2011). Involvement of lysosomal labilisation and lysosomal/mitochondrial cross-talk in diclofenac induced hepatotoxicity. Iran J Pharm Res 10:877-87.
36. Promphan W, Khongphatthanayothin A, Horchaiprasit K, Benjacholamas V. (2003). Roxithromycin induced torsade de pointes in a patient with complex congenital heart disease and complete atrioventricular block. Pacing Clin Electrophysiol 26:1424-6.
37. Ray WA, Murray KT, Hall K, et al. (2012). Azithromycin and the risk of cardiovascular death. New Engl J Med 366:1881-90.
38. Rubart M, Pressler ML, Pride HP, Zipes DP. (1993). Electrophysiological mechanisms in a canine model of erythromycin- associated long QT syndrome. Circulation 88:1832-44.
39. Sanguinetti MC, Jiang C, Curran ME, Keating MT. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307.
40. Shaki F, Hosseini M-J, Ghazi-Khansari M, Pourahmad J. (2012). Toxicity of depleted uranium on isolated rat kidney mitochondria. Biochim Biophys Acta Gen Subjects 1820:1940-50.
41. Shaki F, Hosseini M-J, Ghazi-Khansari M, Pourahmad J. (2013). Depleted uranium induces disruption of energy homeostasis and oxidative stress in isolated rat brain mitochondria. Metallomics 5: 736-44.
42. Stanat SJ, Carlton CG, Crumb Jr WJ, et al. (2003). Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 254:1-7.
43. Uzun C. (2003). Tinnitus due to clarithromycin. J Laryngol Otol 117: 1006-7.
44. Villa P, Sassella D, Corada M, Bartosek I. (1988). Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base. Antimicrob Agents Chemother 32:1541-6.
45. Volberg WA, Koci BJ, Su W, et al. (2002). Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 302:320-7.
46. Weber Jr FH, Richards RD, McCallum RW. (1993). Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 88:485-90.
47. Wormser GP, Dattwyler RJ, Shapiro ED, et al. (2006). The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Diseases 43:1089-134.
48. Zhang Y, Xiao J, Wang H, et al. (2006). Restoring depressed HERG K+channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits. Am J Physiol Heart Circul Physiol 291:H1446-55.
49. Zhao Y, Ye L, Liu H, et al. (2010). Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 104:371-8.